Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

November 30, 2016

Researchers Need to Identify Non-Asbestos Risk Factors for Mesothelioma, Study Suggests

News

A new analysis of occupational links to mesothelioma shows that men with asbestos-related occupations remain to be at risk for the disease. Surprisingly, women holding certain occupations were at risk ... Read more

November 21, 2016

Review Calls for Personalized Approach to Mesothelioma Treatment Development

News

Specific genetic markers need to be identified to allow for personalized treatment of malignant mesothelioma that can be applied once first-line therapy fails, according to a review exploring why newly ... Read more

November 14, 2016

Chemotherapy as Add-on to Surgery Gives Mesothelioma Patients Extra Time, Study Shows

News

Chemotherapy in addition to surgery buys malignant mesothelioma patients extra time, and multimodal treatment increases survival even more. These benefits are independent of the surgical method used, suggesting that multiple ... Read more

November 9, 2016November 9, 2016

Breast Cancer Treatment, Tamoxifen, Seen to Block Mesothelioma in Early Study

News

Tamoxifen, a medication that blocks the effects of estrogen, worked to prevent the growth of malignant pleural mesothelioma cells cultured in the lab, and to improve the cells’ sensitivity to chemotherapy. Interestingly, ... Read more

October 27, 2016

GSK Investigational Drug Prevents Mesothelioma Growth in Mice, Supporting Human Trials

News

A GlaxoSmithKline experimental drug, GSK3052230, prevents tumor growth in mice carrying human mesothelioma tumors. The data supports ongoing investigations of the drug as a mesothelioma treatment. The study, “Inhibition of FGF/FGFR autocrine signaling ... Read more

October 24, 2016

Targeted Antibody Drugs Ineffective in Mesothelioma, Immuno-imaging Shows

News

Using immuno-imaging to assess whether a tumor is likely to react to therapies targeting mesothelin, which is over-expressed in certain cancers, researchers demonstrated that a cancer drug linked to a ... Read more

October 20, 2016

Potential Marker for Pleural Mesothelioma Identified, Improving Prognostic Accuracy

News

Researchers have identified a factor called glycodelin that may serve as a new marker for diagnosing malignant pleural mesothelioma (MPM) and monitoring tumor response to treatment during follow-up. The study, ... Read more

October 14, 2016

Report on Mesothelioma Immunotherapy Suggests Future in Combination Approaches

News

Studies in immune checkpoint blockade against malignant mesothelioma have delivered disappointing results, leading experts to suggest that the future of mesothelioma treatment rests in combination approaches, including immunotherapies and traditional treatments. An extensive ... Read more

October 10, 2016

Features Linked to Drug Resistance of Epithelial Mesothelioma Are Identified

News

The epithelial variant of malignant peritoneal mesothelioma is characterized by molecular changes that give stem cell properties to the cancer cells and promote resistance to cancer drugs, according to a ... Read more